Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate
(NMDA) receptors. The discovery of its rapid antidepressant effects in patients with …

Chronic stress and depressive-like behaviors in basic neuroscience research have been
associated with impairments of neuroplasticity, such as neuronal atrophy and synaptic loss …

Stress is a primary risk factor for several neuropsychiatric disorders. Evidence from
preclinical models and clinical studies of depression have revealed an array of structural …

The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Synaptic loss and deficits in functional connectivity are hypothesized to contribute to
symptoms associated with major depressive disorder (MDD) and post-traumatic stress …

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-
resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of …

Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-
HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific …

Objective: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for
which available pharmacotherapies have limited efficacy. The authors' previous proof-of …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …